- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06058000
A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
September 21, 2023 updated by: Qilu Pharmaceutical Co., Ltd.
A Phase 2, Randomized, Double-blind,Placebo Controlled, Parallel Group Study to Assess Efficacy, Safety, and Pharmacokinetics (PK) of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
The purpose of this study is to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a Phase 2, randomized, double-blind,placebo controlled, parallel group study to assess efficacy, safety, and pharmacokinetics (PK) of QLM3003 Ointment in participants with mild or moderate atopic dermatitis.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mingxia Lv, Master
- Phone Number: 13256161060
- Email: mingxia.lv@qilu-pharma.com
Study Contact Backup
- Name: Xinghua Gao, Doctor
- Phone Number: 024-83283391
- Email: gaobarry@hotmail.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
Contact:
- Xinghua Gao, Doctor
- Phone Number: 024-83283391
- Email: gaobarry@hotmail.com
-
-
Shandong
-
Jinan, Shandong, China, 276000
- Dermatology Hospital of Shandong First Medical University
-
Contact:
- Furen Zhang, Doctor
- Phone Number: 13608921718
- Email: zhangfuren@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The subjects understand and comply with the study requirements, voluntarily participate in the study and sign the informed consent form.
- Ages at ≥18 and ≤ 65 years.
- The diagnosis of atopic dermatitis will be confirmed according to the criteria of Hanifin and Rajka at the Screening Visit and Have a clinical diagnosis of atopic dermatitis for at least 6 months.
- Have an Investigator's Global Assessment (IGA) score of 2, or3 at screening and at baseline.
- Have atopic dermatitis on the head (excluding hair-bearing scalp), neck, trunk, or limbs, covering at least 2% of total BSA and up to and including 20% of total BSA at Screening and at baseline.
Exclusion Criteria:
- Subjects with other dermatologic disease besides AD whose presence or treatments could interfere the assessment of disease (eg, psoriasis).
- In the opinion of the investigator, have any clinically significant laboratory abnormality that would affect the participant's participation in the study.
- Use of topical treatments for AD within 2 weeks of baseline.
- Vaccinated or exposed to a live or attenuated vaccine within the 12 weeks of baseline, or is expected to be vaccinated these vaccines during treatment.
- A history of alcohol or substance abuse within 12 months prior to Screening that in the opinion of the investigator will preclude participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: QLM3003 Low Dose
2% cream applied once daily (QD)
|
QLM3003 topical cream
|
Experimental: QLM3003 Middle Dose
1.5% cream applied twice daily (BID)
|
QLM3003 topical cream
|
Experimental: QLM3003 High Dose
2% cream applied twice daily (BID)
|
QLM3003 topical cream
|
Placebo Comparator: Placebo Comparator: Vehicle
Vehicle cream applied twice daily (BID)
|
Vehicle topical cream
|
Placebo Comparator: High Placebo Comparator: Vehicle
Vehicle cream applied twice daily (BID)
|
Vehicle topical cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 8
Time Frame: Baseline, Weeks 8
|
EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected.
Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe.
EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%).
Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.
|
Baseline, Weeks 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( >=2) Points at Week 8
Time Frame: Baseline, Weeks 8
|
IGA assesses severity of participant's AD on a 5 point scale.
0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.
Higher scores indicating more severity of AD.
Assessment excluded soles, palms and scalp.
|
Baseline, Weeks 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xinghua Gao, Doctor, First Hospital of China Medical University
- Principal Investigator: Furen zhang, Doctor, Dermatology Hospital of Shandong First Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 21, 2023
First Submitted That Met QC Criteria
September 21, 2023
First Posted (Actual)
September 28, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QLM3003-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
-
AnaptysBio, Inc.RecruitingAtopic Dermatitis EczemaUnited States, Canada, Georgia, New Zealand
Clinical Trials on Vehicle (Placebo)
-
Galderma R&DCompleted
-
Eisai LimitedCompleted
-
Taro Pharmaceuticals USACompleted
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Celularity IncorporatedCelgene CorporationTerminatedRheumatoid ArthritisUnited States
-
New York Medical CollegeU.S. Army Medical Research and Development Command; Westchester Medical CenterUnknownStress Disorders, Post-Traumatic | Stress Disorders, Traumatic, AcuteUnited States
-
Taro Pharmaceuticals USACompletedPlaque PsoriasisUnited States
-
Integra LifeSciences CorporationIntegriumTerminatedDiabetic Foot UlcersUnited States
-
Raziel Therapeutics Ltd.Completed
-
Taro Pharmaceuticals USACompletedOnychomycosisUnited States